Is Emend Used for Motion Sickness?
No, Emend (aprepitant) is not used for motion sickness. It's an FDA-approved antiemetic specifically for preventing nausea and vomiting from chemotherapy, surgery, or radiation. Motion sickness involves different triggers like vestibular imbalance, and Emend lacks approval or evidence for it.
What Is Emend Approved For?
Emend blocks NK1 receptors to prevent acute and delayed nausea/vomiting in:
- Highly emetogenic chemotherapy (with dexamethasone and ondansetron).
- Moderately emetogenic chemotherapy.
- Postoperative nausea/vomiting (with dexamethasone).
Dosing is typically 125 mg oral on day 1, then 80 mg daily for 2 days.[1]
Why Not for Motion Sickness?
Emend targets substance P in the central nervous system, which doesn't address motion sickness's histamine, acetylcholine, or vestibular pathways. Clinical trials and labels show no data on this use; off-label application lacks supporting studies and could delay proven treatments.[1][2]
What Works for Motion Sickness Instead?
Standard options include:
- Antihistamines like dimenhydrinate (Dramamine) or meclizine (Bonine), effective for mild cases.
- Anticholinergics like scopolamine patches.
- Ginger or ondansetron for some, though ondansetron is less reliable than for chemo nausea.
Consult a doctor for travel or severe symptoms; combine with behavioral fixes like horizon focus.
Any Overlaps or Risks with Emend?
Patients on Emend for chemo sometimes get motion sickness, but no guidelines recommend it—stick to indicated uses to avoid interactions (e.g., with CYP3A4 drugs) or unneeded expense. Side effects like fatigue or constipation add no benefit here.[1]
[1]: Emend Prescribing Information (Merck)
[2]: Drugs.com - Emend Uses